Bolt Biotherapeutics Ownership
| BOLT Stock | USD 0.76 0.01 1.30% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Bolt |
Bolt Stock Ownership Analysis
About 64.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.4. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bolt Biotherapeutics recorded a loss per share of 1.66. The entity last dividend was issued on the August 29, 2014. The firm had 3:2 split on the January 31, 2008. Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California. Bolt Biotherapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 91 people. For more info on Bolt Biotherapeutics please contact Randall Schatzman at 650 665 9295 or go to https://www.boltbio.com.Besides selling stocks to institutional investors, Bolt Biotherapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Bolt Biotherapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Bolt Biotherapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Bolt Biotherapeutics Quarterly Liabilities And Stockholders Equity |
|
Roughly 3.0% of Bolt Biotherapeutics are currently held by insiders. Unlike Bolt Biotherapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Bolt Biotherapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Bolt Biotherapeutics' insider trades
Bolt Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bolt Biotherapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bolt Biotherapeutics backward and forwards among themselves. Bolt Biotherapeutics' institutional investor refers to the entity that pools money to purchase Bolt Biotherapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Adage Capital Partners Gp Llc | 2024-03-31 | 500 K | Geode Capital Management, Llc | 2024-03-31 | 347.6 K | Blackrock Inc | 2024-03-31 | 255 K | Bridgeway Capital Management, Llc | 2024-03-31 | 111.2 K | Marquette Asset Management Inc. | 2024-03-31 | 96.7 K | Fmr Inc | 2024-03-31 | 78.9 K | Squarepoint Ops Llc | 2024-03-31 | 78 K | Jane Street Group, Llc | 2023-12-31 | 56.3 K | State Street Corporation | 2024-03-31 | 47.4 K | Vivo Capital, Llc | 2024-03-31 | 3.5 M | Tang Capital Management Llc | 2024-03-31 | 3.4 M |
Bolt Biotherapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bolt Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bolt Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bolt Biotherapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lee Frank D. over a month ago Acquisition by Lee Frank D. of 25000 shares of Bolt Biotherapeutics at 1.99 subject to Rule 16b-3 | ||
William Quinn over three months ago Acquisition by William Quinn of 235000 shares of Bolt Biotherapeutics at 1.27 subject to Rule 16b-3 | ||
Randall Schatzman over three months ago Purchase by Randall Schatzman of 2500 shares of Bolt Biotherapeutics | ||
William Quinn over six months ago Purchase by William Quinn of 2500 shares of Bolt Biotherapeutics | ||
Vivo Capital Viii Llc over six months ago Sale by Vivo Capital Viii Llc of 1707 shares of Bolt Biotherapeutics | ||
Vivo Capital Viii Llc over six months ago Sale by Vivo Capital Viii Llc of 7531 shares of Bolt Biotherapeutics | ||
Perez Edith A over a year ago Purchase by Perez Edith A of 2500 shares of Bolt Biotherapeutics |
Pair Trading with Bolt Biotherapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bolt Biotherapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bolt Biotherapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Bolt Stock
| 0.76 | VRDN | Viridian Therapeutics Earnings Call This Week | PairCorr |
Moving against Bolt Stock
| 0.6 | PFE | Pfizer Inc Financial Report 6th of August 2024 | PairCorr |
| 0.54 | ELUT | Elutia Inc Symbol Change | PairCorr |
| 0.34 | MCRB | Seres Therapeutics | PairCorr |
| 0.32 | HOOK | Hookipa Pharma | PairCorr |
| 0.31 | GPCR | Structure Therapeutics | PairCorr |
The ability to find closely correlated positions to Bolt Biotherapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bolt Biotherapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bolt Biotherapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bolt Biotherapeutics to buy it.
The correlation of Bolt Biotherapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bolt Biotherapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bolt Biotherapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bolt Biotherapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Bolt Stock Analysis
When running Bolt Biotherapeutics' price analysis, check to measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.